ArticleJACS Au2026
Selective Chemistry Enables Simultaneous ImmunoPET and Radioimmunotherapy with a Dual-Labeled Probe.
Wei-Siang Mark Kao, Camilla Grimaldi, Zachary V Samuels, Gina Dehlavi, Emilia Strugala, Mike Cornejo, Joni Sebastiano, Lukas M Carter, Brian M Zeglis
Abstract read
In one paragraphArticle in JACS Au, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
9 authors.
Wei-Siang Mark KaoDepartment of Chemistry, Hunter College, The City University of New York, New York, New York 10065, United States.
Camilla GrimaldiDepartment of Chemistry, Hunter College, The City University of New York, New York, New York 10065, United States.
Gina DehlaviDepartment of Chemistry, Hunter College, The City University of New York, New York, New York 10065, United States.
Emilia StrugalaDepartment of Chemistry, Hunter College, The City University of New York, New York, New York 10065, United States.
Mike CornejoDepartment of Chemistry, Hunter College, The City University of New York, New York, New York 10065, United States.
Joni SebastianoDepartment of Chemistry, Hunter College, The City University of New York, New York, New York 10065, United States.
Lukas M CarterDepartment of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York 10065, United States.
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4MNovel Transgenic Mouse Models Addressing Outstanding Translational Barriers in Antibody-Based TherapeuticsR01CA244327 · NCI · ROCKEFELLER UNIVERSITY · PI BOURNAZOS, STYLIANOS · 2020 to 2024
$3.0MAutoantibodies to tumor-derived neoepitopes as biomarkers and immunoPET agents for the early detection of small cell lung cancerR01CA281801 · NCI · FRED HUTCHINSON CANCER CENTER · PI Delphine L Chen, PAUL D. LAMPE · 2023 to 2026
$2.4MNovel Reagents for Rapid and Stable Thiol-Based BioconjugationsR01CA240963 · NCI · HUNTER COLLEGE · PI ZEGLIS, BRIAN MATTHEW · 2019 to 2023
$1.6MThe Ivis Spectrum CT for Pre-Clinical Oncology ResearchS10OD016207 · OD · SLOAN-KETTERING INST CAN RESEARCH · PI ZANZONICO, PAT B · 2013 to 2013
$595kSHARED INSTRUMENT: FOCUS MICROPET: CANCERS10RR020892 · NCRR · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI LARSON, STEVEN MARK · 2005 to 2005
$499kTargeting DNA Mismatches for Auger Electron RadiotherapyR21CA280595 · NCI · HUNTER COLLEGE · PI HUMM, JOHN L, ZEGLIS, BRIAN MATTHEW · 2023 to 2023
$458kThe Development of Radiotherapeutic Paradigms for Desmoplastic Small Round Cell TumorR21CA309945 · NCI · HUNTER COLLEGE · PI Filemon S Dela Cruz, Brian Matthew Zeglis · 2026 to 2026
$431kNCI NIH HHS P30 CA008748NCI NIH HHS R01 CA240963NCI NIH HHS R01 CA244327NCI NIH HHS R01 CA281801NCI NIH HHS R21 CA280595NCI NIH HHS R21 CA309945NCRR NIH HHS S10 RR020892NIH HHS S10 OD016207
6 · The paper itselfAbstract
Theranostics is an emerging paradigm in oncology predicated on using nuclear imaging agents to inform and track treatment with radiotherapeutics. Theranostic workflows typically rely upon the administration of two different radiopharmaceuticals, but this approach requires the development of separate probes and depends upon the assumption that the pharmacokinetic profiles of the agents are identical. Herein, we report the creation of a modular platform that enables simultaneous positron emission tomography (PET) and radioimmunotherapy using a vector labeled with two radionuclides. To this end, we synthesized and validated a trifunctional reagentTzAz-PODSthat facilitates site-selective bioconjugation and allows for the attachment of cargoes via both strain-promoted azide-alkyne and inverse electron-demand Diels-Alder click chemistry. This tool was used to construct an immunoconjugate of the A33 antigen-targeting antibody huA33, which was then labeled in high purity and specific activity with both
Indexed as
5B1A33A33 antigenCA19-9dosimetrydual isotopeinverse electron-demand Diels–Alder click chemistrylutetium-177PETpositron emission tomographyradioimmunotherapyradiopharmaceutical therapyradiotheranosticssite-selective bioconjugationsite-specific bioconjugationstrain-promoted azide−alkyne click chemistrytargeted radionuclide therapytheranosticszirconium-89
Identifiers
PMID42529484
PMCPMC13417245
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390